AnaptysBio, Inc. Profile Avatar - Palmy Investing

AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-3…

Biotechnology
US, San Diego [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

AnaptysBio, Inc. has no acquisition track records yet.

M&A Deals · History

AnaptysBio, Inc. has no acquisition track records yet.

End of ANAB's Analysis
CIK: 1370053 CUSIP: 032724106 ISIN: US0327241065 LEI: - UEI: -
Secondary Listings
ANAB has no secondary listings inside our databases.